Pembrolizumab in PD-L1-positive Advanced Non-Small Cell Lung Carcinoma: A Meta-Analysis Survival Benefits and Immune-related Toxicity Events Patterns: Original scientific article. ADMET DMPK [Internet]. 2025 Oct. 14 [cited 2025 Oct. 24];:2956. Available from: https://pub.iapchem.org/ojs/index.php/admet/article/view/2956